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OBJECTIVES: In the Arimidex, Tamoxifen Alone or in combi-
nation (ATAC) trial, anastrozole produced signiﬁcantly longer
disease-free survival and time to recurrence compared with
tamoxifen in postmenopausal women with hormone receptor-
positive (HR+) early breast cancer after 5 years of treatment
(ATAC Trialists’ Group. Lancet 2005;365:60–2). A cost-effec-
tiveness analysis of anastrozole compared with generic tamox-
ifen was undertaken for inclusion in a submission to the
Australian Pharmaceutical Beneﬁts Advisory Committee (PBAC)
seeking national reimbursement for anastrozole in early breast
cancer. METHODS: A Markov model and Weibull survival
curves ﬁtted to trial data were used to project 5-year outcomes
from the ATAC trial to an actuarial time point of 20 years (a
conservative lifetime equivalent). Resource utilisation data were
obtained from a survey of Australian physicians and the pub-
lished literature. Unit costs (2003–4 AU$) were obtained from
routine sources. A societal perspective was adopted although
indirect costs were not included. Utility scores, derived from a
study in postmenopausal women with early breast cancer, were
incorporated into the model. Costs and beneﬁts were discounted
at the annual rate of 5%. Incremental cost effectiveness ratios
(ICERs), 95% CIs, and acceptability curves were calculated.
RESULTS: The ICERs and 95% CIs for anastrozole compared
with tamoxifen at 20 years were AU$28,532 (AU$16,146–
AU$65,500) per life year gained and AU$24,113 (AU$13,170–
AU$59,357) per QALY gained. There was a greater than 90%
probability that the cost per QALY gained with anastrozole
would be lower than AU$50,000. The results were sensitive to
the time horizon of the model and the assumptions about the
duration of treatment beneﬁt. CONCLUSIONS: Compared with
thresholds accepted in Australia for new drug entities, anastro-
zole is a cost-effective alternative to generic tamoxifen for
primary adjuvant treatment of postmenopausal women with
HR+ early breast cancer.
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OBJECTIVES: NICE Guidance in 2001 recommended vinorel-
bine, paclitaxel, and gemcitabine as part of ﬁrst-line chemother-
apy options for NSCLC patients. Since the Guidance was
published, an oral formulation of vinorelbine and docetaxel has
been introduced in UK. A Markov model has been developed to
realise an indirect comparison of these ﬁve chemotherapies, and
deﬁne their respective level of costs in the NHS’ perspective.
METHODS: Thirteen commonly used regimens including the
oral form with an administration in d8 at home were deﬁned by
a panel of clinical oncologists. In absence of signiﬁcant statisti-
cal difference between the principal criteria of effectiveness, a
cost-minimization study was carried out by allocating to all com-
parators the published data for vinorelbine in Le Chevalier 1999.
The corresponding unit costs of drugs, administration and toxi-
city management, patient transportation costs were gathered
from BNF, PSSRU. The main cost incurring toxicities based on
occurrence in referenced publications were taken into account.
RESULTS: With the conservative assumption of no differences
in therapeutic efﬁcacy, the oral vinorelbine at a dose of 60
mg/m2/week, with one week of rest every 3 weeks, appears as
the least expensive strategy: with an administration in d8 at
home under a general practitioner supervision, its annual follow-
up cost is of £2888; with an outpatient visit in d8, its annual
cost is of £3448. Administrated within a day-hospitalization,
intravenous vinorelbine 25mg/m2 d1 d8, gemcitabine 1250
mg/m2 d1, d8, paclitaxel 175mg/m2 and docetaxel 100mg/m2
incur annual follow-up costs respectively of £3746, £5332,
£5977 and £6766. The oral vinorelbine allows savings of £858
compared to its intravenous form, £2444 compared to gemc-
itabine, £3089 and £3878 compared to paclitaxel and docetaxel
per patient managed for one year. CONCLUSION: Oral vinorel-
bine has a less budgetary impact due to the reduction of the hos-
pital expenditure.
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OBJECTIVES: To evaluate cost of colorectal cancer chemother-
apies (i.e. AIO/Ardalan-regime, Mayo Clinic protocol and oral
capecitabine) in different treatment settings (private ofﬁce, hos-
pital) considering recent changes in drug costs and payment
mechanisms in Germany. METHODS: Resource utilization 
data, derived from 89 quarterly fee-listings for patients with
metastatic colorectal cancer, were re-analyzed using the new
EBM2000plus tariff system (introduced April 05) for ofﬁce-
based physicians, the 2005 DRG-System for hospital treatment
and new regulation on drug prices according to the 2004 health
care reform. Physician’s services, drug costs, pharmacy costs and
costs for implantable venous port systems and single-use pumps
were considered. Several scenarios to reﬂect different assump-
tions were calculated. A third party payer perspective (statutory
sickness funds) was adopted. RESULTS: Depending on the treat-
ment setting (ofﬁce-based, municipal hospital, university hospi-
tal), quarterly treatment costs for the AIO/Ardalan-regimen
varied between €5412 and €15,109, and for the Mayo-Clinic
protocol between €2602 and €4751. Projected costs for
capecitabine were €1980. No hospitalisation was considered to
be necessary for capecitabine due to its oral route of adminis-
tration. Projecting these cost differences to epidemiological data
and treatment pattern information results in a yearly savings
potential of €117 Mio—€214 Mio (depending on assumptions
on hospital care pattern) for German statutory sickness funds by
switching these patients to capecitabine treatment. Compared to
the original analyses, based on cost and payment mechanisms
from 2000, substantial differences were observed. CONCLU-
SION: Treatment using the AIO/Ardalan-protocol was clearly
the most expensive treatment option, treatment using
capecitabine incurred lowest costs. Substantial cost-savings for
sickness funds could be achieved if more patients were treated
with capecitabine. Recent changes in German payment mecha-
